Remikiren

In this article, we will explore the topic of Remikiren and its impact on modern society. From its origins to its current evolution, Remikiren has played a fundamental role in different aspects of daily life. Throughout history, Remikiren has been the subject of debate and controversy, generating diverse opinions and opposing points of view. Through a deep and exhaustive analysis, we will examine the role of Remikiren in various contexts, seeking to understand its influence on culture, politics, economics and other areas of contemporary life. From its historical importance to its future implications, Remikiren has been and will continue to be a topic of interest and relevance in today's world.

Remikiren
Clinical data

ATC code	C09XA01 (WHO)
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2S)-2--N--3-(1H-imidazol-4-yl)propanamide
CAS Number	126222-34-2^Y
PubChem CID	6324659
DrugBank	DB00212^Y
ChemSpider	4884377^Y
UNII	LC7FBL96A4
KEGG	D09038^Y
ChEBI	CHEBI:8803
ChEMBL	ChEMBL31601^Y
CompTox Dashboard (EPA)	DTXSID60155121
Chemical and physical data
Formula	C₃₃H₅₀N₄O₆S
Molar mass	630.85 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=S(=O)(C(C)(C)C)C(C(=O)N(C(=O)N(CC1CCCCC1)(O)(O)C2CC2)Cc3cnc3)Cc4ccccc4
InChI InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1^Y Key:UXIGZRQVLGFTOU-VQXQMPIVSA-N^Y
(verify)

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.^[1]

References

^ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica. 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril^# (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +amlodipine and HCT, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Angiotensin receptor modulators

ATR

Propeptides: Angiotensinogen
Angiotensin I

Combinations:

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.